Literature DB >> 23885791

Biological activity of a standardized freeze-dried platelet derivative to be used as cell culture medium supplement.

Anita Muraglia1, Chiara Ottonello, Raffaele Spanò, Beatrice Dozin, Paolo Strada, Michele Grandizio, Ranieri Cancedda, Maddalena Mastrogiacomo.   

Abstract

Serum of animal origin and in particular fetal bovine serum is the most commonly utilized cell culture medium additive for in vitro cell growth and differentiation. However, several major concerns have been raised by the scientific community regarding the use of animal sera for human cell-based culture applications. Among the possible alternatives to the animal serum, platelet-derived compounds have been proposed since more than 10 years. Nevertheless, the high degree of variability between the different platelet preparations, and the lack of standardized manufacturing and quality control procedures, made difficult to reach a consensus on the applicability of this novel cell culture medium supplement. In this study, we describe the preparation of a standardized platelet-rich plasma (PRP) derivative obtained starting from human-certified buffy coat samples with a defined platelet concentration and following protocols including also freeze-drying, gamma irradiation and biological activity testing prior the product release as cell culture medium additive. Biological activity testing of the different preparations was done by determining the capability of the different PRP preparations to sustain human bone marrow mesenchymal stem cell (MSC) clone formation and proliferation. Taking advantage of a developed MSC in vitro clonogenicity test, we also determined biological activity and stability of the freeze-dried gamma-sterilized PRP preparations after their storage for different times and at different temperatures. The PRP effects on cell proliferation were determined both on primary cell cultures established from different tissues and on a cell line. Results were compared with those obtained in "traditional" parallel control cultures performed in the presence of bovine serum [10% fetal calf serum (FCS)]. Compared to FCS, the PRP addition to the culture medium increased the MSC colony number and average size. In primary cell cultures and in cell line cultures, the PRP promoted cell proliferation also in conditions where the FCS had not a proliferation stimulating effect due to either the nature of the cells and the tissue of origin (such as human articular chondrocytes from elderly patients) or to the critical low density cell seeding (such as for HeLa cells). In summary, the standardized PRP formulation would provide an "off-the-shelf" product to be used for the selection and expansion of several cell types also in critical cell culture conditions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23885791     DOI: 10.3109/09537104.2013.803529

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  17 in total

Review 1.  Platelet-Rich Plasma for the Management of Hip and Knee Osteoarthritis.

Authors:  Kim L Bennell; David J Hunter; Kade L Paterson
Journal:  Curr Rheumatol Rep       Date:  2017-05       Impact factor: 4.592

Review 2.  Platelet-Rich Plasma as an Alternative to Xenogeneic Sera in Cell-Based Therapies: A Need for Standardization.

Authors:  Eduardo Anitua; Mar Zalduendo; Maria Troya; Mohammad H Alkhraisat; Leticia Alejandra Blanco-Antona
Journal:  Int J Mol Sci       Date:  2022-06-11       Impact factor: 6.208

Review 3.  Clinical Update: Why PRP Should Be Your First Choice for Injection Therapy in Treating Osteoarthritis of the Knee.

Authors:  Corey S Cook; Patrick A Smith
Journal:  Curr Rev Musculoskelet Med       Date:  2018-12

4.  Comparison of the efficacy of cryopreserved human platelet lysate and refrigerated lyophilized human platelet lysate for wound healing.

Authors:  Sharon Claudia Notodihardjo; Naoki Morimoto; Natsuko Kakudo; Toshihito Mitsui; Tien Minh Le; Yasuhiko Tabata; Kenji Kusumoto
Journal:  Regen Ther       Date:  2018-11-20       Impact factor: 3.419

5.  Platelet-rich plasma to treat ankle cartilage pathology - from translational potential to clinical evidence: a systematic review.

Authors:  Francesca Vannini; Berardo Di Matteo; Giuseppe Filardo
Journal:  J Exp Orthop       Date:  2015-02-12

Review 6.  Application of platelet-rich plasma with stem cells in bone and periodontal tissue engineering.

Authors:  Gabriela Fernandes; Shuying Yang
Journal:  Bone Res       Date:  2016-12-13       Impact factor: 13.567

Review 7.  Learning from Mother Nature: Innovative Tools to Boost Endogenous Repair of Critical or Difficult-to-Heal Large Tissue Defects.

Authors:  Ranieri Cancedda; Sveva Bollini; Fiorella Descalzi; Maddalena Mastrogiacomo; Roberta Tasso
Journal:  Front Bioeng Biotechnol       Date:  2017-04-28

8.  3D gelatin-chitosan hybrid hydrogels combined with human platelet lysate highly support human mesenchymal stem cell proliferation and osteogenic differentiation.

Authors:  Federica Re; Luciana Sartore; Vladimira Moulisova; Marco Cantini; Camillo Almici; Andrea Bianchetti; Clizia Chinello; Kamol Dey; Silvia Agnelli; Cristina Manferdini; Simona Bernardi; Nicola F Lopomo; Emilio Sardini; Elisa Borsani; Luigi F Rodella; Fabio Savoldi; Corrado Paganelli; Pierangelo Guizzi; Gina Lisignoli; Fulvio Magni; Manuel Salmeron-Sanchez; Domenico Russo
Journal:  J Tissue Eng       Date:  2019-05-02       Impact factor: 7.813

9.  Progenitor Cells Activated by Platelet Lysate in Human Articular Cartilage as a Tool for Future Cartilage Engineering and Reparative Strategies.

Authors:  Simonetta Carluccio; Daniela Martinelli; Maria Elisabetta Federica Palamà; Rui Cruz Pereira; Roberto Benelli; Ana Guijarro; Ranieri Cancedda; Chiara Gentili
Journal:  Cells       Date:  2020-04-23       Impact factor: 6.600

Review 10.  Platelet-rich plasma: why intra-articular? A systematic review of preclinical studies and clinical evidence on PRP for joint degeneration.

Authors:  G Filardo; E Kon; A Roffi; B Di Matteo; M L Merli; M Marcacci
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2013-11-26       Impact factor: 4.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.